Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT06726148
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE)
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06680921
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
- Conditions
- Metastatic Pancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT06663072
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 560
- Registration Number
- NCT06635447
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients with Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC V8Anatomic Stage IV Breast Cancer AJCC V8Stage III Ovarian Cancer AJCC V8Stage III Pancreatic Cancer AJCC V8
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: EchocardiographyProcedure: Multigated Acquisition ScanOther: Survey Administration
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
- Conditions
- CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- GBG Forschungs GmbH
- Target Recruit Count
- 120
- Registration Number
- NCT06607757
- Locations
- 🇩🇪
Hämato-Onkologie im Medicum - Onkologie und Hämatologie, Bremen, Germany
🇩🇪Carl-Thiem-Klinikum gGmbH - Frauenklinik, Cottbus, Germany
🇩🇪Kath. St. Paulus GmbH - Klinische Forschung, Dortmund, Germany
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 260
- Registration Number
- NCT06561022
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
- Conditions
- Advanced Breast CancerLuminal Breast CancerMetastatic Breast CancerHER2-negative Breast CancerER-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 419
- Registration Number
- NCT06525675
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
🇫🇷Hospital Europeo Georges Pompidou AP-HP, Paris, France
🇫🇷Institut Curie, Paris, France
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced And/or Metastatic Breast Cancer
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Biotheryx, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT06515470
- Locations
- 🇺🇸
Biotheryx Investigative Site, Fairfax, Virginia, United States
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
- Conditions
- Advanced/Metastatic Cancer
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06506955
- Locations
- 🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇪🇸Hospital Universitari, Vall d'Hebron, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.